10x Genomics IPO
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems at single-cell resolution. The company's technology enables researchers to study individual cells to better understand complex biological systems, disease mechanisms, and treatment responses. 10x Genomics serves the life sciences research market with applications in oncology, immunology, and neuroscience.
What We Know
10x Genomics went public in September 2019, trading on NASDAQ under the ticker symbol TXG. The company's IPO raised approximately $390 million at $39 per share, significantly above the initial price range. The IPO was well-received by investors, reflecting strong demand for single-cell analysis technology and the company's growth prospects. Since going public, 10x Genomics has continued to innovate in single-cell and spatial biology while expanding its product portfolio and customer base. The company has benefited from growing interest in single-cell research across academic institutions and pharmaceutical companies, though it has also faced competitive pressures and market volatility typical of high-growth technology companies.
Frequently Asked Questions
Has 10x Genomics had an IPO?
Yes, 10x Genomics has been a public company since September 2019. The company went public on NASDAQ under the ticker symbol TXG.
When is the 10x Genomics IPO date?
10x Genomics completed its IPO in September 2019, raising approximately $390 million at $39 per share. The IPO was priced above the initial range due to strong investor demand.
How can I buy 10x Genomics stock?
You can buy 10x Genomics stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol TXG. The stock is available through online brokers and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts